{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:30:08Z","timestamp":1782790208465,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite enormous global investment, translational medical research faces considerable challenges and patients, and their doctors are frequently frustrated by the apparent lack of research activity or progress. Understanding the factors that prevent innovative research discoveries from making it to clinical trials is a multifaceted problem. However, one question that must be addressed is whether the nature of current research activity and the factors that influence the conduct of pre-clinical research, permit, or hamper the timely progression of laboratory-based observations to proof of concept (PoC) clinical trials. Inherent in this question is to what extent a deep mechanistic understanding of a potential new therapy is required before commencing PoC studies, and whether patients are better served when mechanistic and clinical studies progress side by side rather than in a more linear fashion. Here we address these questions by revisiting the historical development of hugely impactful and paradigm-changing innovations in the treatment of hematological cancers. First, we compare the history and route to clinical PoC, of two molecularly-targeted therapies that are BCR:ABL inhibitors in chronic myeloid leukaemia and <jats:italic>all-trans<\/jats:italic> retinoic acid (ATRA) in acute promyelocytic leukaemia (APL). We then discuss the history of arsenic trioxide as additional APL therapy, and the repurposing of thalidomide as effective multiple myeloma therapy. These stories have surprising elements of commonality that demand debate about the modern-day hard and soft governance of medical research and whether these processes appropriately align the priorities of advancing scientific knowledge and the need of patients.<\/jats:p>","DOI":"10.1038\/s41408-022-00738-x","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T02:02:41Z","timestamp":1665108161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-8973","authenticated-orcid":false,"given":"Chris M.","family":"Bunce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-6899","authenticated-orcid":false,"given":"Farhat L.","family":"Khanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Drayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"738_CR1","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/S0140-6736(20)32397-7","volume":"396","author":"C Griffiths","year":"2020","unstructured":"Griffiths C, Mitchell M, Burnand A. More support needed for UK charity-funded medical research. Lancet 2020;396:1616\u20138.","journal-title":"Lancet"},{"key":"738_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF01630378","volume":"8","author":"PC Nowell","year":"1962","unstructured":"Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 1962;8:65\u20136.","journal-title":"Blut"},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290\u20133.","journal-title":"Nature"},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/315758a0","volume":"315","author":"N Heisterkamp","year":"1985","unstructured":"Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph\u2019 translocation. Nature 1985;315:758\u201361.","journal-title":"Nature"},{"key":"738_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 1986;233:212\u20134.","journal-title":"Science"},{"key":"738_CR6","first-page":"204","volume":"5","author":"RL Davis","year":"1985","unstructured":"Davis RL, Konopka JB, Witte ON. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol. 1985;5:204\u201313.","journal-title":"Mol Cell Biol"},{"key":"738_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079\u201382.","journal-title":"Science"},{"key":"738_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990;247:824\u201330.","journal-title":"Science"},{"key":"738_CR9","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","volume":"87","author":"MA Kelliher","year":"1990","unstructured":"Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL. Proc Natl Acad Sci USA 1990;87:6649\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"738_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11912-001-0054-z","volume":"3","author":"MJ Mauro","year":"2001","unstructured":"Mauro MJ, Druker BJ. STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep. 2001;3:223\u20137.","journal-title":"Curr Oncol Rep"},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"738_CR12","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MW Deininger","year":"1997","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691\u20138.","journal-title":"Blood"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","volume":"23","author":"C Gambacorti-Passerini","year":"1997","unstructured":"Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380\u201394.","journal-title":"Blood Cells Mol Dis"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"91","author":"P le Coutre","year":"1999","unstructured":"le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"738_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl J Med. 2001;344:1031\u20137.","journal-title":"N. Engl J Med"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N. Engl J Med. 2017;376:917\u201327.","journal-title":"N. Engl J Med"},{"key":"738_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451\u20138.","journal-title":"Br J Haematol"},{"key":"738_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/archinte.1976.03630070063019","volume":"136","author":"HM Golomb","year":"1976","unstructured":"Golomb HM, Rowley J, Vardiman J, Baron J, Locker G, Krasnow S. Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med. 1976;136:825\u20138.","journal-title":"Arch Intern Med"},{"key":"738_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(77)91415-5","volume":"1","author":"JD Rowley","year":"1977","unstructured":"Rowley JD, Golomb HM, Dougherty C. 15\/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;1:549\u201350.","journal-title":"Lancet"},{"key":"738_CR20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1073\/pnas.67.3.1542","volume":"67","author":"M Paran","year":"1970","unstructured":"Paran M, Sachs L, Barak Y, Resnitzky P. In vitro induction of granulocyte differentiation in hematopoietic cells from leukemic and non-leukemic patients. Proc Natl Acad Sci USA 1970;67:1542\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"738_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1073\/pnas.70.2.343","volume":"70","author":"E Fibach","year":"1973","unstructured":"Fibach E, Hayashi M, Sachs L. Control of normal differentiation of myeloid leukemic cells to macrophages and granulocytes. Proc Natl Acad Sci USA 1973;70:343\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"738_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/299063a0","volume":"299","author":"E Gootwine","year":"1982","unstructured":"Gootwine E, Webb CG, Sachs L. Participation of myeloid leukaemic cells injected into embryos in haematopoietic differentiation in adult mice. Nature 1982;299:63\u20135.","journal-title":"Nature"},{"key":"738_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood.V57.6.1000.1000","volume":"57","author":"TR Breitman","year":"1981","unstructured":"Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981;57:1000\u20134.","journal-title":"Blood"},{"key":"738_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0145-2126(86)90265-1","volume":"10","author":"C Chomienne","year":"1986","unstructured":"Chomienne C, Balitrand N, Degos L, Abita JP. 1-B-D arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells. Leuk Res. 1986;10:631\u20136.","journal-title":"Leuk Res"},{"key":"738_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(89)90812-X","volume":"2","author":"C Chomienne","year":"1989","unstructured":"Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, et al. Retinoic acid therapy for promyelocytic leukaemia. Lancet 1989;2:746\u20137.","journal-title":"Lancet"},{"key":"738_CR26","first-page":"949","volume":"1002","author":"ME Huang","year":"1987","unstructured":"Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Rep. 6 cases Chin Med J (Engl) 1987;1002:949\u201353.","journal-title":"Rep. 6 cases Chin Med J (Engl)"},{"key":"738_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567\u201372.","journal-title":"Blood"},{"key":"738_CR28","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.V82.11.3241.3241","volume":"82","author":"P Fenaux","year":"1993","unstructured":"Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241\u20139.","journal-title":"Blood"},{"key":"738_CR29","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","volume":"100","author":"MS Tallman","year":"2002","unstructured":"Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298\u2013302.","journal-title":"Blood"},{"key":"738_CR30","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505\u201315.","journal-title":"Blood"},{"key":"738_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/330624a0","volume":"330","author":"V Giguere","year":"1987","unstructured":"Giguere V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330:624\u20139.","journal-title":"Nature"},{"key":"738_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/330444a0","volume":"330","author":"M Petkovich","year":"1987","unstructured":"Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444\u201350.","journal-title":"Nature"},{"key":"738_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00702866","volume":"80","author":"MG Mattei","year":"1988","unstructured":"Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon P. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet. 1988;80:186\u20138.","journal-title":"Hum Genet"},{"key":"738_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","volume":"66","author":"A Kakizuka","year":"1991","unstructured":"Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663\u201374.","journal-title":"Cell"},{"key":"738_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","volume":"66","author":"H de The","year":"1991","unstructured":"de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675\u201384.","journal-title":"Cell"},{"key":"738_CR36","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354\u201360.","journal-title":"Blood"},{"key":"738_CR37","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u201353.","journal-title":"Cancer Res"},{"key":"738_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cpt196563292","volume":"6","author":"KB Olson","year":"1965","unstructured":"Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-Phthaloylglutamimide) in the Treatment of Advanced Cancer. Clin Pharm Ther. 1965;6:292\u20137.","journal-title":"Clin Pharm Ther"},{"key":"738_CR39","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"738_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"BM Kenyon","year":"1997","unstructured":"Kenyon BM, Browne F, D\u2019Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971\u20138.","journal-title":"Exp Eye Res"},{"key":"738_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","volume":"87","author":"A Vacca","year":"1994","unstructured":"Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503\u20138.","journal-title":"Br J Haematol"},{"key":"738_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ajh.2830500103","volume":"50","author":"A Vacca","year":"1995","unstructured":"Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol. 1995;50:9\u201314.","journal-title":"Am J Hematol"},{"key":"738_CR43","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl J Med. 1999;341:1565\u201371.","journal-title":"N. Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00738-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T03:29:23Z","timestamp":1665113363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00738-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00738-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}